<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384107</url>
  </required_header>
  <id_info>
    <org_study_id>V114-033</org_study_id>
    <secondary_id>V114-033</secondary_id>
    <secondary_id>2019-003644-68</secondary_id>
    <secondary_id>205287</secondary_id>
    <nct_id>NCT04384107</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and immunogenicity of a 4-dose
      schedule (3-dose primary series followed by a toddler dose) of V114 compared with
      Pneumococcal 13-valent Conjugate Vaccine (PCV13). The hypothesis is that V114 is non-inferior
      to PCV13 for the 13 shared serotypes between V114 and PCV13 based on response rates at 30
      days following Dose 3 and that V114 is superior to PCV13 for the 2 serotypes unique to V114
      based on the response rates at 30 days following Dose 3.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Injection-Site Adverse Events</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs could be swelling, redness, pain or tenderness, and hard lump.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Systemic AEs</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs could be irritability, drowsiness, appetite loss, and hives or welts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Vaccine-Related Serious Adverse Events</measure>
    <time_frame>~1 month after Dose 4 (Up to 23 months)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific Immunoglobulin G Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 3</measure>
    <time_frame>30 Days after Dose 3</time_frame>
    <description>Assess the anti-pneumococcal polysaccharide (PnPs) serotype-specific immunoglobulin G (IgG) response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114 as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-Specific IgG for Each Serotype in V114 After Dose 3</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG geometric mean concentrations (GMCs) of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114 as measured by the Pn ECL assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific IgG Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114 as measured by the Pn ECL assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of Serotype-Specific IgG for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG GMCs of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114 as measured by the Pn ECL assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-Specific Opsonophagocytic Activity for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific opsonophagocytic activity (OPA) and geometric mean titers (GMTs) of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL subcutaneous injection of V114 at approximately 2, 3, 4, and 12-15 months of age (Study Day 1, Month 1, Month 2, and Month 10-13).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumococcal 13-valent Conjugate Vaccine (PCV13)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL subcutaneous injection of PCV13 at approximately 2, 3, 4, and 12-15 months of age (Study Day 1, Month 1, Month 2, and Month 10-13).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>Pneumococcal 13-valent Conjugate Vaccine (PCV13)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female

          -  Has a legally acceptable representative who understands the study procedures,
             alternate treatments available, and risks involved with the study and voluntarily
             agrees to participate by giving written informed consent. The legally acceptable
             representative may also provide consent for future biomedical research. However, the
             participant may participate in the main study without participating in future
             biomedical research.

        Exclusion Criteria:

          -  Has a history of invasive pneumococcal disease (IPD) (positive blood culture, positive
             cerebrospinal fluid culture, or other sterile site) or known history of other culture
             positive pneumococcal disease.

          -  Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine
             (PCV), or any diphtheria toxoid containing vaccine.

          -  Has a known or suspected impairment of immunological function.

          -  Has a history of congenital or acquired immunodeficiency.

          -  Has or his/her mother has a documented human immunodeficiency virus (HIV) infection.

          -  Has or his/her mother has a documented hepatitis B surface antigen - positive test.

          -  Has known or history of functional or anatomic asplenia.

          -  Has failure to thrive based on the clinical judgement of the investigator.

          -  Has a history of autoimmune disease (including but not limited to systemic lupus
             erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid
             disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or
             other autoimmune disorders).

          -  Has a known neurologic or cognitive behavioral disorder, including
             encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development
             disorder, and related disorders.

          -  Has received a dose of any pneumococcal vaccine prior to study entry.

          -  Has received a blood transfusion or blood products, including immunoglobulins.

          -  Has participated in another clinical study of an investigational product before the
             beginning or anytime during the duration of the current clinical study. Participants
             enrolled in observational studies may be included; these will be reviewed on a
             case-by-case basis for approval by the Sponsor.

          -  Has any other reason that, in the opinion of the investigator, may interfere with the
             evaluation required by the study. Reasons may include, but are not limited to, being
             unable to keep appointments or planning to relocate far away during the study.

          -  Has an immediate family member (e.g, spouse, parent/legal guardian, sibling, or child)
             who is investigational site or Sponsor staff directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Social Medical Corporation Koujunkai Daido Clinic ( Site 3326)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-52-611-6262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sotobo Children's Clinic ( Site 3323)</name>
      <address>
        <city>Isumi</city>
        <state>Chiba</state>
        <zip>299-4503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-470-80-2622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokoyama Children's Clinic ( Site 3309)</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-581-1203</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chugoku Rosai Hospital ( Site 3340)</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-823-72-7171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JOHAS Yokohama Rosai Hospital ( Site 3343)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-474-8111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aizawa Hospital ( Site 3313)</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-263-33-8600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taniguchi Hospital ( Site 3310)</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>598-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-463-3232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical corporation Waffle GunGunkids Clinic ( Site 3329)</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-275-8502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Takatsuki General Hospital ( Site 3318)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-681-3801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aiwa Hospital ( Site 3336)</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-49-235-8811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hara Children's Clinic ( Site 3339)</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-4-2926-4333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobayashi Pediatric Clinic ( Site 3301)</name>
      <address>
        <city>Fujieda</city>
        <state>Shizuoka</state>
        <zip>426-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-54-635-2620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nishida Kodomo Clinic ( Site 3306)</name>
      <address>
        <city>Tama</city>
        <state>Tokyo</state>
        <zip>206-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-42-376-1001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukui Aiiku Hospital ( Site 3315)</name>
      <address>
        <city>Fukui</city>
        <zip>910-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-776-54-5757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shimomura Pediatrics Clinic ( Site 3320)</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-883-5232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saiseikai Noe Hospital ( Site 3330)</name>
      <address>
        <city>Osaka</city>
        <zip>536-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6932-0401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sano Kids Clinic ( Site 3341)</name>
      <address>
        <city>Osaka</city>
        <zip>553-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6940-6105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Shizuoka Hospital ( Site 3322)</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-54-254-4311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hosaka Children's Clinic ( Site 3307)</name>
      <address>
        <city>Tokyo</city>
        <zip>112-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3946-0641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okawa Children &amp; Family Clinic ( Site 3305)</name>
      <address>
        <city>Tokyo</city>
        <zip>146-0095</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3758-0920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama City Hospital ( Site 3328)</name>
      <address>
        <city>Toyama</city>
        <zip>939-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-76-422-1112</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

